![]() | Lizenz: Creative Commons Namensnennung 4.0 International PDF - Veröffentlichte Version (430kB) |
- URN zum Zitieren dieses Dokuments:
- urn:nbn:de:bvb:355-epub-584094
- DOI zum Zitieren dieses Dokuments:
- 10.5283/epub.58409
Zusammenfassung
Background The increasing prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) incurs substantial morbidity, mortality and healthcare costs. Detection and clinical intervention at early stages of disease improves prognosis; however, we are currently limited by a lack of reliable diagnostic tests for population screening and monitoring responses to therapy. To address ...
![plus plus](/style/images/plus.png)
Nur für Besitzer und Autoren: Kontrollseite des Eintrags